Skip to main content
Log in

Health Implications of Drug Interactions

  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

The awareness of the digoxin-quinidine interaction in the mid-70s led to increased interest in drug interactions. Much has been published on the subject in the form of interaction reports, handbooks, lists, cards, discs etc. However, only a few interactions in the literature have clinical significance and can be remembered by thinking in terms of groups, pharmacokinetics and probabilities.

It is important to realise that drugs in a given class will have similar properties. Thus, phenylbutazone, like any other nonsteroidal anti-inflammatory drug (NSAID), is likely to potentiate the effects of warfarin. A knowledge of drug pharmacokinetics is also essential; a highly protein-bound drug may displace another when they are administered together. Remembering those drugs which induce liver enzyme formation will prevent their co-administration with drugs which have a critical dose-range. If a general practitioner can remember the few drugs in clinical practice with a narrow therapeutic index, he can consult a handbook before anything else is prescribed.

Some interactions will rarely be encountered in daily general practice, i.e. those associated with tuberculosis treatment or anaesthetic agents. Other interactions, e.g. the interaction between antihypertensive treatment and over-the-counter medication containing phenylpropanolamine, are more common.

While most drug interactions can be avoided by thinking in terms of groups, pharmacokinetics and probabilities, some learning by rote is required, e.g. the potential for heart failure with concomitant β-blocker and nifedipine therapy.

In general, a schematic approach using thinking in terms of groups, pharmacokinetics and probabilities will prevent most clinically significant drug interactions; the rest can be avoided by consulting appropriate handbooks and specialists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • D’Arcy PF. Drug interactions. In D’Arcy PF, Griffin JP (Eds) Iatrogenic diseases, 3rd ed., p. 921, Oxford University Press, Oxford, New York & Tokyo, 1986

    Google Scholar 

  • Dukes MNG, Swartz B. Responsibility for drug-induced injury. Elsevier Science Publishers, Amsterdam, New York & Oxford, 1988

    Google Scholar 

  • Editorial. Drug interactions. Lancet 1: 904–905, 1975

  • Frey W. Über Vorhofflimmern beim Menschen und seine Beseitigung durch Chinidin. Klinische Wochenschrift 55: 450–452, 1918

    Google Scholar 

  • Loeliger EA, Broekmans AW. Drugs affecting blood clotting, fibrinolysis and hemostasis. In Dukes MNG (Ed.) Meyler’s side effects of drugs, 11th ed., pp. 733–775, Elsevier Science Publishers, Amsterdam, New York & Oxford, 1988

    Google Scholar 

  • Urquhart J, Heilmann K. Risk watch: the odds of life. Facts on File Publications, New York & Bicester, 1984

    Google Scholar 

  • Withering W. An account of the foxglove, and some of its medical uses. Robinson, Birmingham, 1785

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dukes, M.N.G. Health Implications of Drug Interactions. Drug-Safety 5 (Suppl 1), 84–87 (1990). https://doi.org/10.2165/00002018-199000051-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199000051-00013

Keywords

Navigation